The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review

Overview

Journal J Dev Biol

Specialty Biology

Date 2022 Aug 23

PMID 35997395

Authors

Daniel Halloran

Venu Pandit

Anja Nohe

Affiliations

Soon will be listed here.

Abstract

Protein kinase CK2 (CK2) is a ubiquitous holoenzyme involved in a wide array of developmental processes. The involvement of CK2 in events such as neurogenesis, cardiogenesis, skeletogenesis, and spermatogenesis is essential for the viability of almost all organisms, and its role has been conserved throughout evolution. Further into adulthood, CK2 continues to function as a key regulator of pathways affecting crucial processes such as osteogenesis, adipogenesis, chondrogenesis, neuron differentiation, and the immune response. Due to its vast role in a multitude of pathways, aberrant functioning of this kinase leads to embryonic lethality and numerous diseases and disorders, including cancer and neurological disorders. As a result, CK2 is a popular target for interventions aiming to treat the aforementioned diseases. Specifically, two CK2 inhibitors, namely CX-4945 and CIBG-300, are in the early stages of clinical testing and exhibit promise for treating cancer and other disorders. Further, other researchers around the world are focusing on CK2 to treat bone disorders. This review summarizes the current understanding of CK2 in development, the structure of CK2, the targets and signaling pathways of CK2, the implication of CK2 in disease progression, and the recent therapeutics developed to inhibit the dysregulation of CK2 function in various diseases.

Citing Articles

Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia.

Li J, Ye C, Li H, Li J Cancer Biol Ther. 2025; 26(1):2457777.

PMID: 39862423 PMC: 11776473. DOI: 10.1080/15384047.2025.2457777.

Protein kinase CK2 sustains de novo fatty acid synthesis by regulating the expression of SCD-1 in human renal cancer cells.

Guerra B, Jurcic K, van der Poel R, Cousineau S, Doktor T, Buchwald L Cancer Cell Int. 2024; 24(1):432.

PMID: 39726006 PMC: 11674369. DOI: 10.1186/s12935-024-03611-y.

Methyl-Beta-Cyclodextrin Restores Aberrant Bone Morphogenetic Protein 2-Signaling in Bone Marrow Stromal Cells Obtained from Aged C57BL/6 Mice.

Halloran D, Pandit V, Chukwuocha K, Nohe A J Dev Biol. 2024; 12(4).

PMID: 39585031 PMC: 11586967. DOI: 10.3390/jdb12040030.

The ARK2N-CK2 complex initiates transcription-coupled repair through enhancing the interaction of CSB with lesion-stalled RNAPII.

Luo Y, Li J, Li X, Lin H, Mao Z, Xu Z Proc Natl Acad Sci U S A. 2024; 121(24):e2404383121.

PMID: 38843184 PMC: 11181095. DOI: 10.1073/pnas.2404383121.

Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis.

Oami T, Abtahi S, Shimazui T, Chen C, Sweat Y, Liang Z Proc Natl Acad Sci U S A. 2024; 121(10):e2217877121.

PMID: 38412124 PMC: 10927519. DOI: 10.1073/pnas.2217877121.

References

Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F . Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 2005; 12(6):668-77. DOI: 10.1038/sj.cdd.4401604. View

Schneider H, Reichert G, Issinger O . Enhanced casein kinase II activity during mouse embryogenesis. Identification of a 110-kDa phosphoprotein as the major phosphorylation product in mouse embryos and Krebs II mouse ascites tumor cells. Eur J Biochem. 1986; 161(3):733-8. DOI: 10.1111/j.1432-1033.1986.tb10501.x. View

Bender M, Schwind L, Grundmann D, Martin M, Klotz M, Gotz C . Impact of protein kinase CK2 inhibitors on proliferation and differentiation of neural stem cells. Heliyon. 2017; 3(6):e00318. PMC: 5470557. DOI: 10.1016/j.heliyon.2017.e00318. View

Zhou N, Li Q, Lin X, Hu N, Liao J, Lin L . BMP2 induces chondrogenic differentiation, osteogenic differentiation and endochondral ossification in stem cells. Cell Tissue Res. 2016; 366(1):101-11. DOI: 10.1007/s00441-016-2403-0. View

Trembley J, Wang G, Unger G, Slaton J, Ahmed K . Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009; 66(11-12):1858-67. PMC: 4385580. DOI: 10.1007/s00018-009-9154-y. View

Hauck L, Harms C, An J, Rohne J, Gertz K, Dietz R . Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med. 2008; 14(3):315-24. DOI: 10.1038/nm1729. View

Rodriguez F, Allende C, Allende J . Protein kinase casein kinase 2 holoenzyme produced ectopically in human cells can be exported to the external side of the cellular membrane. Proc Natl Acad Sci U S A. 2005; 102(13):4718-23. PMC: 555726. DOI: 10.1073/pnas.0501074102. View

Kim J, Lee H, Kim N, Shin C, Lee S, Park Y . Prevalence and clinicopathologic characteristics of gastric cardia cancer in South Korea. Helicobacter. 2012; 17(5):358-68. DOI: 10.1111/j.1523-5378.2012.00958.x. View

Taylor K, Hiscox S, Nicholson R, Hogstrand C, Kille P . Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7. Sci Signal. 2012; 5(210):ra11. PMC: 3428905. DOI: 10.1126/scisignal.2002585. View

10.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

11.

Rane N, Kang S, Chakrabarti O, Feigenbaum L, Hegde R . Reduced translocation of nascent prion protein during ER stress contributes to neurodegeneration. Dev Cell. 2008; 15(3):359-370. PMC: 2563805. DOI: 10.1016/j.devcel.2008.06.015. View

12.

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M . The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. PMC: 5480189. DOI: 10.1186/s12964-017-0177-y. View

13.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, OBrien S . CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24):10288-98. DOI: 10.1158/0008-5472.CAN-10-1893. View

14.

Lou D, Dominguez I, Toselli P, Landesman-Bollag E, OBrien C, Seldin D . The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol. 2007; 28(1):131-9. PMC: 2223292. DOI: 10.1128/MCB.01119-07. View

15.

Nguyen J, Kelly S, Wood R, Heubel B, Nohe A . A Synthetic Peptide, CK2.3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway. J Dev Biol. 2020; 8(3). PMC: 7557985. DOI: 10.3390/jdb8030012. View

16.

Benavent Acero F, Capobianco C, Garona J, Cirigliano S, Perera Y, Urtreger A . CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models. Lung Cancer. 2016; 107:14-21. DOI: 10.1016/j.lungcan.2016.05.026. View

17.

Hartung A, Bitton-Worms K, Rechtman M, Wenzel V, Boergermann J, Hassel S . Different routes of bone morphogenic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol. 2006; 26(20):7791-805. PMC: 1636853. DOI: 10.1128/MCB.00022-06. View

18.

Park J, Bae Y . Downregulation of JMJD2a and LSD1 is involved in CK2 inhibition-mediated cellular senescence through the p53-SUV39h1 pathway. BMB Rep. 2022; 55(2):92-97. PMC: 8891621. View

19.

Ishihara K, Yamagishi N, Hatayama T . Protein kinase CK2 phosphorylates Hsp105 alpha at Ser509 and modulates its function. Biochem J. 2003; 371(Pt 3):917-25. PMC: 1223342. DOI: 10.1042/BJ20021331. View

20.

Pluemsampant S, Safronova O, Nakahama K, Morita I . Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors. Int J Cancer. 2007; 122(2):333-41. DOI: 10.1002/ijc.23094. View